Assessing the efficacy and safety in novel drug candidates for Alzheimer's disease requires a rigorous evaluation system. Preclinical studies often involve in vitro and in vivo assays to assess its potential efficacy in targeting disease-related pathways. Once promising candidates emerge, they enter clinical trials which are conducted on human vol